Skip to main content

Table 1 Patient baseline demographics and clinical characteristics at enrollment (n = 30)

From: Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization

Patient Characteristics Parameters Overall n (%) 1 month PCS within 2SD of NBS (n = 18) 1 month PCS > 2SD below NBS (n = 12) p-value
Age Median (range) 62 (35–82) 60.8 61.3 0.46
Gender Male 23 (77%) 13 10 0.31
Female 7 (23%) 5 2
Ethnicity White 24 (80%) 14 10 0.37
Black 4 (13%) 3 1
Other 2 (7%) 1 1
HCC Etiology HCV 16 (53%) 10 6 0.42
HBV 2 (7%) 1 1
ALD 5 (17%) 3 2
Other causes of cirrhosis 7 (23%) 4 3
Non-Liver Comorbidities (e.g. Hypertension, Diabetes) Present 22 (73%) 14 8 0.25
Absent 8 (27%) 4 4
Portal Hypertension Present 20 (67%) 11 9 0.43
Absent 10 (33%) 7 3
Hepatic Encephalopathy Present 3 (10%) 1 2 0.33
Absent 27 (90%) 17 10
Child-Pugh Class A 20 (67%) 11 9 0.19
B 10 (33%) 7 3
C 0 (0%) 0 0
ECOG Performance Status 0 13 (43%) 9 4 0.17
1 17 (57%) 9 8
Tumor Morphology Tumor Locations Unilobar 19 (63%) 12 7 0.82
Bilobar 11 (37%) 6 5
Number of Nodules Solitary 11 (37%) 7 4 0.23
Multiple 19 (63%) 11 8
Mean largest tumor size (cm) 9.2 (4.9–19) 9.7 9.1 0.04
Mean largest tumor volume (cm3) 588 (145–1136) 580 602 0.42
Tumor Burden <50% 20 (67%) 11 9 0.20
50%–75% 10 (33%) 7 3
>75% 0 (0%) 0 0
Portal Vein Thrombosis (PVT) Presence Present 30 (100%) 18 12 0.26
Absent 0 (0%) 0 0
Location Main PV 6 (20%) 4 2 0.63
Branch PV 24 (80%) 14 10
Degree of Occlusion Occlusive 23 (77%) 13 10 0.30
Non-Occlusive 7 (23%) 5 2
Laboratory Data Mean Serum AFP (ng/dl) 715 (3.3 to >2400) 703 801 0.36
Previous Treatment No 10 (33%) 7 3 0.22
Yes 20 (67%) 11 9
Type of Previous Treatmenta cTACE/DEB-TACE 14 (47%) 10 4 0.19
RFA 0 (0%) 0 0
Liver Resection 0 (0%) 0 0
Sorafeniba 6 (20%) 4 2
Lung Shunt Fraction (LSF) Mean (%) 11.0 (5.1–19.8) 11.3 10.8 0.52
  1. PCS Physical Component Summary Scores, SD Standard Deviation, ECOG Eastern Cooperative Oncology Group, PVT Portal Vein Thrombosis, cTACE Conventional Transarterial Chemoembolization, DEB-TACE Drug-Eluting Bead Transarterial Chemoembolization, RFA Radiofrequency Ablation
  2. aIndicates number of patients who were taking Sorafenib at the time of 90Y. A total of 17 patients (55%) had been on Sorafenib at the time of or prior to receiving 90Y therapy
  3. Bold data are statistically significant (P <0.05)